Adult acute lymphoblastic leukemia: concepts and strategies.
Adult acute lymphoblastic leukemia: concepts and strategies.
复制标题
DOI：
10.1002/cncr.24862
复制
发表时间：
2010-03-01
期刊：
影响因子：
6.2
通讯作者：
Kantarjian HM
中科院分区：
文献类型：
--
作者：
Faderl S;O'Brien S;Pui CH;Stock W;Wetzler M;Hoelzer D;Kantarjian HM
急性淋巴细胞白血病（ALL）是一种造血母细胞的克隆性扩增，是一种高度异质性的疾病，包括许多实体，其治疗策略不同。虽然ALL在儿科肿瘤学中是一个成功的故事，但成人的结果落后于儿童。新药的扩展，更可靠的免疫学和分子技术用于评估微小残留病，以及更精确的风险分层正在产生成人ALL治疗的新方面。在这篇综述中，作者总结了有关ALL生物学和治疗的最新文献，并讨论了成人ALL管理新方法的当前策略和潜在意义。
Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL.